|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.5 CNY | +5.31% |
|
+4.83% | +5.54% |
| 24/05 | Mabwell Announces 9MW2821 Clinical Data | CI |
| 13/05 | Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer | CI |
Mabwell (Shanghai) Bioscience Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 89.88 million compared to CNY 10.99 million a year ago. Revenue was CNY 89.96 million compared to CNY 11.05 million a year ago.
Net loss was CNY 413.53 million compared to CNY 423.28 million a year ago. Basic loss per share was CNY 1.03 compared to CNY 1.06 a year ago. Diluted loss per share was CNY 1.03 compared to CNY 1.06 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +5.54% | 1.81B | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. 
